Quoin Pharmaceuticals: Share Price Soars More Than 30% on News of Second Clinical Trial
Clinical-stage specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX) plans to initiate a multicenter open label study of its lead product, QRX003, in Netherton Syndrome (NS) patients who are currently receiving systemic biologic therapy.
A subset of NS patients is being treated off-label with systemic biologics that provide some symptomatic relief but do not address all symptoms, nor the underlying cause of the disease. Assessing the safety and efficacy of the QRX003 as adjuvant treatment with a systemic biologic could potentially generate valuable clinical data and better treatment options for patients.
- The multicenter, open label study will be conducted under Quoin’s currently open U.S. Investigational New Drug (IND) Application;
- It will assess QRX003 topical lotion in NS patients who are currently receiving treatment, including systemic therapy for symptomatic relief;
- A number of different clinical endpoints will be assessed in the study.
NS is a rare and devastating genetic disease. If approved, QRX003 has the potential to become the standard of care for NS patients. Quoin’s share price rose more than 30% on the news.